Spyre Therapeutics Inc. Cash Flow-to-Debt Ratio
Spyre Therapeutics Inc. cash flow-to-debt ratio. Spyre Therapeutics Inc. (SYRE) has a Cash Flow-to-Debt Ratio of -0.97x as of June 2026, meaning its operating cash flow of $-69.88 Million could theoretically repay -1% of its total liabilities ($71.86 Million) in one year. See Spyre Therapeutics Inc. (SYRE) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Spyre Therapeutics Inc. (2014–2025)
Cash flow-to-debt ratio of Spyre Therapeutics Inc. from 2014 to 2025. Historical debt coverage capacity for Spyre Therapeutics Inc. across 12 annual periods. Check SYRE cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Spyre Therapeutics Inc. Cash Flow-to-Debt Ratio by Year (2014–2025)
Spyre Therapeutics Inc. cash flow-to-debt ratio by year from 2014 to 2025. Year-by-year debt coverage analysis for Spyre Therapeutics Inc.. For the full cash flow conversion analysis, see Spyre Therapeutics Inc. (SYRE) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.71x | $-169.25 Million | $62.55 Million | ▼ -55.9% |
| 2024 | -1.74x | $-157.41 Million | $90.68 Million | ▼ -174.2% |
| 2023 | -0.63x | $-99.91 Million | $157.84 Million | ▲ +83.5% |
| 2022 | -3.85x | $-80.14 Million | $20.84 Million | ▼ -86.0% |
| 2021 | -2.07x | $-53.72 Million | $25.98 Million | ▲ +40.6% |
| 2020 | -3.48x | $-75.78 Million | $21.79 Million | ▼ -22.3% |
| 2019 | -2.84x | $-65.69 Million | $23.10 Million | ▲ +8.9% |
| 2018 | -3.12x | $-32.19 Million | $10.31 Million | ▲ +27.2% |
| 2017 | -4.29x | $-24.61 Million | $5.74 Million | ▲ +6.7% |
| 2016 | -4.60x | $-18.84 Million | $4.10 Million | ▼ -6.8% |
| 2015 | -4.31x | $-10.98 Million | $2.55 Million | ▲ +37.9% |
| 2014 | -6.93x | $-7.33 Million | $1.06 Million | — |